Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology sabatolimab - TIM3 antagonist sabatolimab - TIM3 antagonist References Abbreviations Other Indication NCT03946670 STIMULUS MDS-1 (CMBG453B12201) Myelodysplastic syndrome Indication Phase Phase 2 Phase NCT04150029 STIMULUS-AML1 (CMBG453C12201) Unfit acute myeloid leukaemia Phase 2 Patients 120 Patients 86 Primary Complete Remission (CR) rate and Progression Free Survival (PFS) Primary Outcome Outcome Measures Measures Arms Intervention Experimental: Sabatolimab (MBG453) + hypomethylating agents Placebo comparator: Placebo + hypomethylating agents Arms Intervention Target Patients Adult subjects with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as per IPSS-R criteria Target Patients Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy Read-out Milestone(s) 2022 Read-out Milestone(s) 2023 ClinicalTrial.gov dates for reference: Primary Completion: 29-Apr-2022; Secondary Completion: 10-Aug-2024 Publication TBD Publication 77 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation